Faruqi and Faruqui, LLP Logo
Share this page

Sagent Pharmaceuticals, Inc. (SGNT)



Faruqi & Faruqi, LLP Announces the Investigation of Sagent Pharmaceuticals, Inc. (SGNT) Over the Proposed Sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd.

Nadeem Faruqi, founding partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Sagent Pharmaceuticals, Inc. (“Sagent” or the “Company”) (NASDAQ:SGNT) for potential breaches of fiduciary duties in connection with the sale of the Company to Nichi-Iko Pharmaceutical Co., Ltd. for approximately $736 million. 

The Company’s stockholders will only receive $21.75 in cash for each share of Company common stock they own. However, this consideration is below at least one analyst’s price target of $25.00 per share and Sagent’s 52-week high of $26.47 per share.

If you own common stock in Sagent and wish to obtain additional information and protect your investments free of charge, please fill out the form below or contact Nadeem Faruqi, Esq. either via e-mail at nfaruqi@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.  You may also contact Juan E. Monteverde, Esq.  either via email at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Request Information

Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.

  • Company:
    Sagent Pharmaceuticals, Inc. (SGNT)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Nadeem Faruqi
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 07/12/2016

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.